Proactive Investors - Run By Investors For Investors

Squarex looks to raise $20 mln to develop its drug to prevent cold sores

Squarex CEO Hugh McTavish joined Proactive Investors at the 11th Annual BioTech Showcase in San Francisco.

Squarex is a clinical stage pharmaceutical company developing a topical formulation to prevent recurrent cold sores and other infections caused by Herpes Simplex Virus 1 or Herpes Simplex Virus 2.

View full SQRE profile View Profile

Squarex Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use